

# How to efficiently update non-compliant Early Development trial to meet submission requirements

Qianqian Cheng / Principal Statistical Programming Lead

2025-08-29





**2025 CHINA CDISC DAY | BEIJING**

**How to efficiently update non-compliant Early Development  
trial to meet submission requirements**

Presented by Qianqian Cheng, C&SP, Johnson&Johnson



# Meet the Speaker

**Qianqian Cheng**


**Title:** Statistical Programming Lead

**Organization:** Janssen China R&D, Johnson & Johnson

Qianqian Cheng graduated from Fudan University in 2012. She had worked as Statistical programmer at Pfizer for more than 4 years. She Joined Johnson & Johnson as Oncology TA statistical programmer lead in 2017, and supported the approval of Darzalex clinical study in Multiple Myeloma and Amyloidosis, and CARVYTI in Multiple Myeloma Due-Diligence, NMPA submission, inspection and approval. Currently, she focuses on two CAR-T clinical studies in Lymphoma.


# Disclaimer and Disclosures

- *The views and opinions expressed in this presentation are those of the author(s) and do not necessarily reflect the views or policies of Johnson & Johnson.*
- *The author(s) have no real or apparent conflicts of interest to report.*
- *The data analysis in this presentation is based on dummy data, with no real data involved. The results are for illustrative purposes only and have no practical significance.*




# Agenda

1. Background
2. Challenges & Solutions & Case Sharing
3. Summary



# Background

- Features of Early Development (ED)
- Background of Clinical Trial




## • Features of Early Development (ED)


- Short (relatively short project timelines)
- Frequent (high delivery frequency)
- Fast (tight schedules)

# Background of Overall Clinical Trial

- **Indication:** CAR-T Study in Lymphoma
- **Primary Endpoint:** Safety + RP2D (Recommended Phase2 Dose)
- **Milestone:** Supported 2 SET Meetings (1 SET/3Month)
- **Analysis Scope:** 5 ADaMs + 20~TFLs
- **Potential Plan:** Link with Phase2 Study
- **Resource:** Limited



# Challenges & Solutions & Case Sharing



# Challenges & Solutions 01 - Data

## ➤ Challenge :

- ADaMs Metadata: missing label for variables
- Variable Name is non-compliant
- ADaMs Structure/purpose

## ➤ Solution :




- Analysis Drive : SAP/TFLs purpose to Metadata
- Change the variable name based on CDISC guideline
- Remove unnecessary ADaM

# Case Sharing

## ➤ Variable Name is non-compliant:

- Original Name:
  - CAR-T infusion: TRTS1SDT/TRTS1EDT (Safety baseline)
  - Lymphodepletion: TRTO1SDT/ TRTO1EDT, TRTO2SDT/ TRTO2EDT (Efficacy baseline)
- CDISC ADaM IG:
  2. The lower case letters “w”, “xx”, “y”, and “zz” that appear in a variable name or label in this document must be replaced in the actual variable name or label using the following conventions.
    - a. The lower-case letter “w” in a variable name (e.g., PHwSDT, PxwSwSDT) is an index for the  $w^{\text{th}}$  variable where “w” is replaced with a single digit [1-9].
    - b. The letters “xx” in a variable name (e.g., TRTxnP, APxxSDT) refer to a specific period where “xx” is replaced with a zero-padded two-digit integer [01-99]. The use of ‘xx’ within a variable name is restricted to the concept of a period.




# Case Sharing

- P21 Validation Report:

Pinnacle 21 Enterprise Validation Report						
Dataset	Values	Rule ID	Publisher ID	Message	FDA	PMDA
ADSL	TRCSDT	AD1019	+	Illegal variable name: xx is not in [01-99] for an ADSL trial date	Error	Error
ADSL	TRCAEDTM	AD1019	+	Illegal variable name: xx is not in [01-99] for an ADSL trial date	Error	Error
ADSL	TRCAEDT	AD1019	+	Illegal variable name: xx is not in [01-99] for an ADSL trial date	Error	Error
ADSL	TRCASDTM	AD1019	+	Illegal variable name: xx is not in [01-99] for an ADSL trial date	Error	Error
ADSL	TRCASDT	AD1019	+	Illegal variable name: xx is not in [01-99] for an ADSL trial date	Error	Error

- Updated Name:

Variable Name	Label
CTRTSDT	CAR-T Start Date
CTRTEDT	CAR-T End Date
FLTRTSDT	Fludarabine Start Date
FLTRTEDT	Fludarabine End Date
CYTRTSDT	Cyclophosphamide Start Date
CYTRTEDT	Cyclophosphamide End Date



## Challenges & Solutions 02 - Code

➤ **Challenge :**

- Code is not organized - Difficult to understand and update
- A lot of derivation rules are in TFL program
- QC code is not in tracker

➤ **Solution :**


- Set up program/macro conventions
- Re-organize all programs/macros – readable
- Derivation code in TFLs -> ADaMs parameter
- QC code should be promoted for tracker

# Case Sharing

## ➤ Make the code into sections and clear specification/purpose



ClearDataClearImpact



## Challenges & Solutions 03

➤ **Challenge :**

- Early Development Study may have many run-in groups/exploratory subgroup analysis based on diff indications

➤ **Solution : = Efficient + Smart work**

- Insert the flexible button in TFLs program
- Add the flags in ADSL
- Centralize to control the TFL Layout
- Set up the TFL programs convention

# Case Sharing

## ➤ Insert the flexible button in TFLs program:

### Scenario 01:

```
*****  
%macro trtgroup(DSN);  
data &DSN.;  
  set &DSN.;  
  if trt01an in (1,2) then _COLVAR = 1;  
  else if trt01an in (3,4,5,6) then _COLVAR = 2;  
  else if trt01an in (7,8,9,10,11,12) then _COLVAR = 3;  
run;  
  
%end trtgroup;
```


### Scenario 02:

```
*****  
%macro trtgroup(DSN);  
data _ads1;  
  set a_in.ads1;  
  where FUD28FL="Y";  
  keep usubjid;  
  proc sort; by usubjid;  
run;  
  
data _dsn;  
  set &DSN.;  
  proc sort; by usubjid;  
run;  
  
data _dsn01;  
  merge _ads1(in=a) _dsn;  
  by usubjid;  
  if a;  
run;  
  
data &DSN01;  
  set &DSN01;  
  if trt01an in (1,2) then _COLVAR = 1;  
  else if trt01an in (3,4,5,6) then _COLVAR = 2;  
  else if trt01an in (7,8,9,10) then _COLVAR = 3;  
  else if trt01an in (11,12) then _COLVAR = 4;  
run;  
  
%end trtgroup;
```



Call this macro in TFLs program

```
options validvarname =upcase mprint nomlogic nosymbolgen;  
  
%trtgroup(dsn = ads1);  
%trtgroup(dsn = slae);
```




## Challenges & Solutions 04

### ➤ Challenge :

- Phase1b link with Phase2
- Phase1b+Phase2 in one database **VS** phase1b/2 diff in some CRF pages
- Phase1b and Phase2: Diff TFL Layout


### ➤ Solution :

- Attend CRF Setup/review Meeting
- Evaluate the potential update to impact SDTM structure
- Evaluate the potential ADaMs update based on updated SDTM structure
- Efficiently produce the Phase1b/2 TFLs



# Case Sharing


- 1 set of programs are built up
- Use the Replace App to update program by batch
- 3 potential Sets programs: xxxPH1, XXXPH2,XXXRP2D



# Summary

**Proactive evaluate potential risk from submission, set up Database/code conventions in study start-up**

- Programming Lead should have the big/whole picture from startup to Submission, from study to compound(pooled analysis)
- Empower/inspire supporting programmers
- Set up the regular programming meeting ( Follow-up/Timely-update)
- Set up the compound programming conventions (keep the compound consistent)



# Thank You!

